ProKidney Corp.

ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases in the United States. Its lead product candidate is rilparencel, an autologous selected renal cell therapy currently in Phase III clinical trials for advanced chronic kidney disease and type 2 diabetes. The company is also developing cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008, both in Phase III trials. Its pipeline includes earlier-stage candidates: REGEN-002, REGEN-003, and REGEN-007 in Phase II, and REGEN-004 in Phase I. These therapies aim to address the underlying causes of kidney disease by using the patient's own renal cells to restore kidney function.

ProKidney Corp. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol PROK. Its shares trade in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in Winston-Salem, North Carolina, and its operations are based in the US market.

ProKidney Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative cell therapies for chronic kidney diseases. Biotechnology companies like ProKidney typically engage in research and development of therapeutic products derived from biological sources, often requiring extensive clinical trials and regulatory approvals before commercialization.

ProKidney Corp. is headquartered in Winston-Salem, North Carolina, United States. The company primarily serves the US market, as indicated by its country and region designations. Its clinical trials and development activities are focused on addressing chronic kidney diseases, which affect a significant portion of the US population. The company's therapies are designed to treat conditions like advanced chronic kidney disease and type 2 diabetes, which are prevalent in the US healthcare system.

ProKidney Corp. is a clinical-stage biotechnology company that does not yet have approved products or revenue from product sales. Its business model centers on developing cell therapies for chronic kidney diseases through rigorous clinical trials. The company's lead product, rilparencel, is an autologous selected renal cell therapy in Phase III trials for advanced chronic kidney disease and type 2 diabetes. It also has cryopreserved versions (REGEN-006 and REGEN-008) in Phase III, and earlier-stage candidates: REGEN-002, REGEN-003, and REGEN-007 in Phase II, and REGEN-004 in Phase I. The company's value depends on successful trial outcomes, regulatory approvals, and eventual commercialization, potentially through partnerships or direct sales.